3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
54
Phase 2
43
Phase 1
23
Phase 1/2
14
Phase 4
10
Phase 2/3
2
Phase NA
1
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
OTHER
11
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Breast Neoplasms
1
Interventions
fludarabine
9
Cyclophosphamide
9
pembrolizumab
5
Oncolytic Virotherapy
4
Nivolumab
4
Cholestanetriol 26-Monooxygenase
3
atezolizumab
2
alpha-Synuclein
2
Trastuzumab
2
Influenza Vaccines
2
Blood Specimen Collection
2
Ascorbic Acid
2
tinostamustine
1
sugemalimab
1
spartalizumab
1
ruxolitinib
1
reolysin
1
pexidartinib
1
methyl prednisolonate
1
irinotecan sucrosofate
1
fiu protein, E coli
1
camrelizumab
1
avelumab
1
apatinib
1
VTX-2337
1
Temozolomide
1
TAK-981
1
Sorafenib
1
Radiation
1
RXDX-106
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
INDUSTRY
×
Letrozole
×
Clear all
NCT04102618
2022-08-15
AWARE-1
Oncolytics Biotech
Phase EARLY_PHASE1
Terminated
26 enrolled